Photoaging
Conditions
Keywords
Extracellular matrix, Hyaluronic acid, dermal filler
Brief summary
The purpose of the study is to investigate the impact of the injection of dermal filler on the quality of the skin dermal extracellular matrix in persons between the ages of 30-50 years. The quality of the dermal extracellular matrix will be assessed following injection of dermal filler compared to injection of saline vehicle.
Interventions
DEVICERestylane-L
Using a small gauge metal hub needle, two injections of CL-HA dermal filler (Restylane-L) will be performed, each into a small area (approximately 2 x 2 cm) of the mid-dermis of a forearm of a subject. Each injection will be 0.5 cc in volume, and will be approximately 2 cm apart from each other
DEVICEVehicle
Two injections of vehicle will be performed in the same manner as Restylane-L and in the same forearm, totaling 4 injections. A plastic template will be used to track the location of the injections, relative to landmarks on the skin.
Sponsors
University of Michigan
Galderma R&D
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
30 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* Subjects must understand and sign the informed consent prior to participation * Subjects must be in generally good health * Subjects must be able and willing to comply with the requirements of the protocol
Exclusion criteria
* Pregnant, plan to become pregnant during the study, or are nursing a child. Participants will be asked to self-report pregnancy * Individuals with bleeding disorders * Tend to heal poorly or form very thick scars called keloids * Have a lidocaine sensitivity, including those with epilepsy, impaired cardiac conduction, severely impaired hepatic function or severe renal dysfunction. * Individuals with active inflammation or infection of the skin, including active herpes infection. * Have a significant medical history or concurrent condition which the investigator(s) feel is not safe for study participation, including history of frequent herpes infections, and subjects planning to be exposed to excessive sun, Ultraviolet lamps and extreme cold weather during the first week after injection. * History of allergies to gram positive bacterial proteins * Individuals with who have undergone therapy with thrombolytics, anticoagulants, or inhibitors of platelet aggregation in the preceding 3 weeks. * Have an active inflammation or infection of the skin near the site of injection * Are taking any medications that suppress your immune system * Have severe allergies to medications or other things that we believe might make participation unsafe for you * Have a history of connective tissue diseases, such as: * rheumatoid arthritis * scleroderma * polymyositis/dermatomyositis * systemic lupus erythematosus (SLE)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Extracellular Matrix (ECM) deposition as measured using histological stain(s) of skin | Approximately 4 weeks | Reported as a semi-quantitative grade. The grading scale is 1-4. The higher the number to increased ECM deposition. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORGary Fisher
University of Michigan
Outcome results
None listed